A Study of ERY974 in Patient With Advanced Solid Tumors
Status: | Active, not recruiting |
---|---|
Conditions: | Cancer |
Therapuetic Areas: | Oncology |
Healthy: | No |
Age Range: | 18 - Any |
Updated: | 2/8/2019 |
Start Date: | August 2016 |
End Date: | December 2019 |
A Phase 1 Dose Escalation and Cohort Expansion Study of ERY974, An Anti-Glypican3 (GPC3)/CD3 Bispecific Antibody, in Patients With Advanced Solid Tumors
This is the open label, multicenter Phase 1 study which consists of a dose escalation to
determine the maximum tolerated dose (MTD) and cohort expansion to obtain a preliminary
evaluation of anti-tumor activity. ERY974 is intravenously injected to patients with Glypican
3 positive advanced solid tumors until unacceptable toxicity or disease progression.
determine the maximum tolerated dose (MTD) and cohort expansion to obtain a preliminary
evaluation of anti-tumor activity. ERY974 is intravenously injected to patients with Glypican
3 positive advanced solid tumors until unacceptable toxicity or disease progression.
Inclusion Criteria:
- Male or female patient with Glypican 3 positive advanced solid tumor not amenable to
standard therapy or for which standard therapy is not available or not indicated
- Measurable tumor
- Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1
- Adequate bone marrow, liver, and renal function
- Adequate coagulation status
Exclusion Criteria:
- Patients with more than a single brain metastasis ( >1 cm)
- Patients with acute or chronic infection
- Major surgery within 28 days
- Pregnant or lactating women
- Patients with interstitial pneumonitis
- Patients require regular ascites/pleural effusion drainage
We found this trial at
8
sites
Click here to add this to my saved trials

Click here to add this to my saved trials

Click here to add this to my saved trials

Click here to add this to my saved trials

Click here to add this to my saved trials

Click here to add this to my saved trials

Click here to add this to my saved trials

Click here to add this to my saved trials
